Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic intervention.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
28 03 2023
Historique:
entrez: 21 3 2023
pubmed: 22 3 2023
medline: 24 3 2023
Statut: ppublish

Résumé

The receptor tyrosine kinase KIT and its ligand stem cell factor (SCF) are required for the development of hematopoietic stem cells, germ cells, and other cells. A variety of human cancers, such as acute myeloid leukemia, gastrointestinal stromal tumor, and mast cell leukemia, are driven by somatic gain-of-function KIT mutations. Here, we report cryo electron microscopy (cryo-EM) structural analyses of full-length wild-type and two oncogenic KIT mutants, which show that the overall symmetric arrangement of the extracellular domain of ligand-occupied KIT dimers contains asymmetric D5 homotypic contacts juxtaposing the plasma membrane. Mutational analysis of KIT reveals in D5 region an "Achilles heel" for therapeutic intervention. A ligand-sensitized oncogenic KIT mutant exhibits a more comprehensive and stable D5 asymmetric conformation. A constitutively active ligand-independent oncogenic KIT mutant adopts a V-shaped conformation solely held by D5-mediated contacts. Binding of SCF to this mutant fully restores the conformation of wild-type KIT dimers, including the formation of salt bridges responsible for D4 homotypic contacts and other hallmarks of SCF-induced KIT dimerization. These experiments reveal an unexpected structural plasticity of oncogenic KIT mutants and a therapeutic target in D5.

Identifiants

pubmed: 36943885
doi: 10.1073/pnas.2300054120
pmc: PMC10068818
doi:

Substances chimiques

Proto-Oncogene Proteins c-kit EC 2.7.10.1
Ligands 0
Receptor Protein-Tyrosine Kinases EC 2.7.10.1
Stem Cell Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2300054120

Références

Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
J Mol Biol. 2015 Dec 4;427(24):3921-34
pubmed: 26463591
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7681-6
pubmed: 18505839
Mol Cell. 2015 Jan 8;57(1):191-201
pubmed: 25544564
Physiol Rev. 2012 Oct;92(4):1619-49
pubmed: 23073628
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
J Struct Biol. 2021 Jun;213(2):107702
pubmed: 33582281
Elife. 2013 Sep 10;2:e01456
pubmed: 24040512
Cell. 2007 Jul 27;130(2):323-34
pubmed: 17662946
EMBO J. 2007 Feb 7;26(3):891-901
pubmed: 17255936
Nat Methods. 2008 Jan;5(1):53-5
pubmed: 18157137
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4784-93
pubmed: 27482095
Clin Cancer Res. 2008 Apr 15;14(8):2285-94
pubmed: 18413817
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
J Biol Chem. 1997 Mar 7;272(10):6311-7
pubmed: 9045650
Elife. 2019 Aug 22;8:
pubmed: 31436533
Commun Biol. 2021 Jul 15;4(1):874
pubmed: 34267316
Cell Signal. 2013 Nov;25(11):2231-8
pubmed: 23880320
Protein Sci. 2021 Jan;30(1):70-82
pubmed: 32881101
PLoS One. 2009 Aug 06;4(8):e6529
pubmed: 19657394
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Nat Rev Cancer. 2012 Nov;12(11):753-66
pubmed: 23076159
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Elife. 2018 Nov 09;7:
pubmed: 30412051
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7732-7
pubmed: 10884405
Mol Biotechnol. 2013 Jun;54(2):461-8
pubmed: 22825855
Acta Crystallogr D Struct Biol. 2018 Jun 1;74(Pt 6):519-530
pubmed: 29872003
Nat Struct Mol Biol. 2011 Aug 07;18(9):984-9
pubmed: 21822280
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1772-7
pubmed: 24449920
Nat Rev Cancer. 2011 Nov 17;11(12):865-78
pubmed: 22089421
Nat Methods. 2020 Dec;17(12):1214-1221
pubmed: 33257830
Pharmacol Res. 2018 Jul;133:35-52
pubmed: 29704617
Nature. 2021 Dec;600(7888):339-343
pubmed: 34759323
Nat Commun. 2019 Oct 8;10(1):4567
pubmed: 31594955
Cell. 1990 Apr 20;61(2):203-12
pubmed: 2158859
Expert Opin Investig Drugs. 2013 Jan;22(1):103-15
pubmed: 23127174
Mol Cancer Res. 2009 Sep;7(9):1525-33
pubmed: 19737976
Elife. 2021 Nov 30;10:
pubmed: 34846302

Auteurs

Stefan G Krimmer (SG)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Nicole Bertoletti (N)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Yoshihisa Suzuki (Y)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Luka Katic (L)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Jyotidarsini Mohanty (J)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Sheng Shu (S)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Sangwon Lee (S)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Irit Lax (I)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Wei Mi (W)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Joseph Schlessinger (J)

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH